Gregg H. Alton
2017
In 2017, Gregg H. Alton earned a total compensation of $5.2M as Former Interim Chief Executive Officer and Chief Patient Officer at Gilead Sciences.
Compensation breakdown
| Non-Equity Incentive Plan | $1,132,000 |
|---|---|
| Option Awards | $1,599,915 |
| Salary | $956,308 |
| Stock Awards | $1,518,203 |
| Other | $10,000 |
| Total | $5,216,426 |
Alton received $1.6M in option awards, accounting for 31% of the total pay in 2017.
Alton also received $1.1M in non-equity incentive plan, $956.3K in salary, $1.5M in stock awards and $10K in other compensation.
Rankings
In 2017, Gregg H. Alton's compensation ranked 1,771st out of 14,666 executives tracked by ExecPay. In other words, Alton earned more than 87.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,771 out of 14,666 | 88th |
Division Manufacturing | 592 out of 5,772 | 90th |
Major group Chemicals And Allied Products | 156 out of 2,075 | 93rd |
Industry group Drugs | 112 out of 1,731 | 94th |
Industry Biological Products, Except Diagnostic Substances | 22 out of 313 | 93rd |
Source: SEC filing on March 24, 2020.
Alton's colleagues
We found five more compensation records of executives who worked with Gregg H. Alton at Gilead Sciences in 2017.